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Abstract
This thesis is the result of a three month internship at TCG Pharmaceuticals, Singapore.
With the worldwide initiative of lean in TCG, it has implemented the TCG Production
System which finds its roots in the famous Toyota Production System. The recognition of
the importance of reducing the waste of inventory by TCG is the main motivational force
for this internship. This thesis documents the inventory levels of the finished goods in the
current production scenario and also analyzes the inventory levels for the future as the
production of a new product is aimed to be launched this year. The main purpose of this
thesis is to suggest ways to better manage the finished goods inventory at TCG. The
future states are modeled using a single stage multi product system and various scenarios
are developed. A comparison is made between the TCG's planned production schedule
and the production schedules developed based on the different scenarios generated using
the model. The performance is measured in terms of the space that is needed in each case
to hold the inventory.
Thesis Advisors:
Prof. Stephen C. Graves Abraham J. Siegel Professor of Management Science
MIT Sloan School of Management
Teo Tiak Lim Company Supervisor
2
Acknowledgements
First and foremost, I would like to thank my thesis advisor, Prof Stephen C. Graves for
his continued support throughout my internship and during the process of writing this
thesis. I am grateful for his patience, guidance and careful analysis of the project.
I would also like to thank TCG, Singapore for sponsoring me in my improvement in the
Manufacturing Systems and Technology program with MIT. I wish to thank the TCG
employees who helped me in the data collection phase and answered my repeated
questions with sincerity and patience. Special thanks goes to my company supervisor Mr.
Teo Tiak Lim, who provided the necessary guidance and continuous encouragement, Mr.
Charles Shank, the sponsor of the project for his motivational speeches, Mr. Nicolas
Almeida and Mr. Sunil Chandiramani.
I am grateful to the people involved in the Manufacturing program at MIT especially Prof.
David Hardt, Dr. Brian Anthony, Prof. Stephen Graves, Prof. Jeremie Gallien, Prof.
Stanley Gershwin and Prof Kamal Youcef-Toumi for making this program a rewarding
experience. Dr. Brian Anthony deserves particular recognition. He served as a
coordinator, encourager and a friend. His trips to Singapore were inspirational.
I thank Mr. Tom Knight, MIT alumnus and the Founder and Chief Strategy Officer of
Invistics Corporation, who shared his much valued experience and time with me.
Kind thanks goes to my thesis co-workers and friends Yixiong Kok and Thomas Khor,
who were a wonderful team to work with.
Finally, I wish to thank my parents who have always motivated me to give my best.
3
Table of Contents
1. Introduction ..................................................................... 9
1.1 Background and Motivation .......................................................................... 9
1.2 TCG Manufacturing Facilities ........................................................................ 9
1.3 Products........................................................................................................ . 10
1.4 The Motivation for the Internship................................................................. 10
1.5 O bjective ......................................................................................................... 11
1.6 Organization of the Thesis............................................................................. 13
2. The TCG Singapore Operations..... 14
2.1 Products........................................................................................................ . 14
2.2 The Production Facilities and the Supply Chain studied.............................. 17
2.2.1 The Pharmaceutical Facility 1 .............................................................. 18
2.2.2 The API Facility.................................................................................... 21
2.3 Customer Demand Forecasting...................................................................... 22
2.4 The ERP and the Planning Activities............................................................. 23
3. Finished Goods Inventory ................................................... 25
3.1 The A pproach................................................................................................ 25
3.2 Finished Goods Inventory Trends................................................................. 26
3.2.1 Planning for Pharmaceutical Facility 1 Production .............................. 30
3.3 The Customer Demand and the Forecast Accuracy...................................... 32
3.4 Future Changes ............................................................................................. 42
3.4.1 Forecast for Product B .......................................................................... 43
4
4. Production scheduling and Inventory calculations.............. 44
4.1 Campaign Production Model........................................................................ 44
4.1.1 M odel Setup ........................................................................................... 47
4.2 Models for Comparison with current TCG plan............................................ 59
4.2.1 Model Improvements............................................................................. 66
4.3 Evaluation of the Model................................................................................ 70
4.3.1 M odel A ssum ptions ............................................................................... 73
4.3.2 M odel Lim itations.................................................................................. 74
5. Conclusions and Recommendations.................................... 75
5.1 Further Research Suggestions...................................................................... 76
6. Bi.bliography ......................................... 77
5
List of Figures
Figure 1: Supply chain diagram 17
Figure 2: Pharmaceutical Facility 1 production facility 20
Figure 3: API production facility 22
Figure 4: Inventory distribution history 27
Figure 5: Percentage distribution of the different inventory categories 27
Figure 6: Historical inventory trend by product 29
Figure 7: Production sequence for different Product A strengths 31
Figure 8: Forecast projection history for February 2007 34
Figure 9: Forecast projection history for March 2007 35
Figure 10: Forecast projection history for April 2007 35
Figure It: Forecast projection history for February 07 for different strength of
Product A 37
Figure 12: Forecast projection history for March 2007 for different strength of
Product A 37
Figure 13: Forecast projection history for April 2007 for different strength of
Product A 38
Figure 14: Variance of forecast error for Pharmaceutical Facility 1 - Non
Aggregated 39
Figure 15: Variance of forecast error for Pharmaceutical Facility I - Aggregated 40
Figure 16: Projection of the C.V. of the Forecast Error for Pharmaceutical Facility
1 41
Figure 17: Production campaigning model for two product types 45
Figure 18: Monthly pallet space distribution for 2008 for Scenario 1 55
Figure 19: Monthly pallet space distribution for 2008 for Scenario II 59
Figure 20: Monthly inventory distribution for 2008 for Scenario III 65
Figure 21: Monthly inventory distribution for 2008 for Scenario IV 69
Figure 22: Monthly pallet space distribution for 2008 for the planned TCG MPS 71
6
List of Tables
Table 1: Current TCG products and their production status 14
Table 2: Finished Products differentiation and respective markets 15
Table 3: New Product A Types - differentiation and respective markets 16
Table 4: Cycle times for three stages of Product A supply chain 28
Table 5: Product B demand forecast for the year 2008 43
Table 6: Summary of the various Scenarios generated using the Single Stage Two
Product Model 48
Table 7: Demand data for first six months for Scenario I 48
Table 8: Model inputs for first six months for Scenario 1 49
Table 9: Cycle length Calculation for first six months for Scenario I 49
Table 10: Demand data for last six months for Scenario I 50
Table 11: Model inputs for last six months for Scenario 1 51
Table 12: Cycle length Calculation for last six months for Scenario I 51
Table 13: Master production schedule for Scenario I 52
Table 14: Calculation of safety stock for Scenario I 53
Table 15: Monthly FG Inventory distribution for Scenario I 54
Table 16: Model inputs for first six months for Scenario II 56
Table 17: Cycle length Calculation for first six months for Scenario II 56
Table 18: Model inputs for last six months for Scenario II 57
Table 19: Cycle length Calculation for last six months for Scenario II 57
Table 20: Master production schedule for Scenario II 58
Table 21: Calculation of safety stock for Scenario II 58
Table 22: Monthly FG Inventory distribution for Scenario II 58
Table 23: Demand data for first six months for Scenario III 60
Table 24: Model inputs for first six months for Scenario III 61
Table 25: Cycle length Calculation for first six months for Scenario III 61
Table 26: Demand data for last six months for Scenario III 62
Table 27: Model inputs for last six months for Scenario III 62
7
Table 28: Cycle length Calculation for last six months for Scenario III 63
Table 29: Master production schedule for Scenario III 63
Table 30: Safety stock calculation for Scenario III 64
Table 31: Monthly FG Inventory distribution for Scenario III 64
Table 32: Model inputs for first six months for Scenario IV 66
Table 33: Cycle length Calculation for first six months for Scenario IV 67
Table 34: Model inputs for last six months for Scenario IV 67
Table 35: Cycle length Calculation for last six months for Scenario IV 68
Table 36: Master production schedule for Scenario IV 68
Table 37: Safety stock calculation for Scenario IV 68
Table 38: Monthly FG Inventory distribution for Scenario IV 69
Table 39: Master production schedule currently planned by TCG for 2008 70
Table 40: Monthly FG Inventory distribution for MPS 2008 70
Table 41: Adjusted monthly FG Inventory distribution for MPS 2008 71
Table 42: Inventory comparison between the planned MIPS and proposed scenarios
72
8
1. Introduction
1.1 Background and Motivation
This thesis is the result of a three month internship at TCG Pharmaceuticals, Singapore.
TCG is a leading research-driven pharmaceutical company which produces a wide range
of innovative health care products, directly and through its joint ventures. TCG,
Singapore was incorporated in the year 1998 and started the production for its first batch
in the year 2001.
1.2 TCG Manufacturing Facilities
The company has divided the whole facility into three different manufacturing facilities;
The Active Pharmaceutical Ingredient (API) Facility, Pharmaceutical Facility 1, and the
Pharmaceutical Facility 2. The first TCG chemical manufacturing plant in the Asia
Pacific region, this new facility is an advanced, flexible and multi-product operation
capable of producing active ingredients and chemical intermediates for several TCG
products. This facility produced its first batch of product in the month of May 2001.
The Pharmaceutical Facility I was constructed in the year 2003 and produced the first
batch of products in the year 2004. This pharmaceutical facility supports TCG's
worldwide supply for Product A.
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The third manufacturing facility is the newest of the three and is called as Pharmaceutical
Facility 2. The facility is currently doing the production validation of a new TCG product
and a full production of the new product is expected to start later in the year 2007.
1.3 Products
The products produced by TCG can be broadly categorized into two different types based
on their usage and customers. These are the Active Product Ingredients and the Product
Stock Keeping Units (SKUs) which are the tablets. The Active Product Ingredients are
the products that are the chemical intermediates and are further used in the production of
the SKUs. These chemical intermediates are produced at the API facility. The SKUs are
produced at the Pharmaceutical Facility 1.
Currently the API facility produces two different products. These are products are
Product C and Product D. The Pharmaceutical Facility 1 produces one main product
currently known as Product A and is a combination of Raw Material 4 and Product C.
Product A is further classified into four different types based on its strength.
The Pharmaceutical Facility 2 is currently producing a new product called Product B for
the clinical trials. Starting at the end of the year 2007, TCG expects to receive the
approval from the FDA for Product B and then to start the full production of the product
at this facility.
1.4 The Motivation for the Internship
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TCG Singapore owns its own warehouse located inside the facility. This warehouse
serves to store the raw materials that are required for the products produced at API,
Pharmaceutical Facility 1 and the Pharmaceutical Facility 2, the packaging material that
is required to contain and package these products, the intermediate products produced by
API facility for the further use of Pharmaceutical Facility 1, and the finished goods
(SKUs) produced by both the API facility and the Pharmaceutical Facility 1. Millions of
dollars of inventory are stored in this warehouse at any given point of time. The
motivation of this thesis is to examine the substantial amount of space required in the
warehouse for carrying this inventory.
1.5 Objective
This thesis is a result of a three month internship by three graduate students from the
Mechanical Engineering Department at Massachusetts Institute of Technology, at TCG
Singapore. The internship period covered the entire material planning and management
process at TCG. We realized in the beginning that though the lean manufacturing which
started at Toyota has established its roots in various manufacturing industries, the lean
concepts and their application are fairly new to the pharmaceutical industry. This may be
because of the special needs of the pharmaceutical industry and the way these companies
design their manufacturing operations. But recently many pharmaceutical companies
have started to go the "lean way". TCG introduced a huge lean initiative in the year 2005
and the company is on its way to implement the lean concepts modified to their own
needs and goals. Regardless of the amount of lean literature that we reviewed, trying to
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develop a model for inventory management was a big challenge for us because of the
limited information available on the lean concepts in pharmaceutical industries.
The main goals of this internship are:
1. To help reduce the amount of space required to store this inventory without
affecting the production and the customer service level.
2. To help improve the material ordering and production planning process that will
help achieve the reduction in the inventory.
The overall objective of the internship was divided into three theses, each focused on a
different area and collectively aiming to achieve the main goal of the internship, that is,
to reduce the amount of space required in the warehouse to store the material.
The resulting three theses, one by each graduate student, focused on the following three
areas:
1. Managing the raw material inventories
2. Managing the inventories of the products produced at the API facility
3. Managing the inventories of the finished goods produced at Pharmaceutical Facility 1
This thesis will only deal with the third area studied during the whole internship. I also
want to acknowledge that the section 3.3 is taken from the thesis by my team mate,
Thomas Si Ming Khor.
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1.6 Organization of the Thesis
Chapter 2 will describe the details of the products that are produced at TCG, the overall
facility layouts, the planning process at TCG, and the production facilities in terms of
their capacities and constraints.
Chapter 3 will document the production planning process used for Pharmaceutical
Facility 1, finished goods inventory trends, the demand forecasts and the future changes
in the production scheduling approach. Chapter 4 will describe the single stage two
product production scheduling model that I recommend for Pharmaceutical Facility 1.
Chapter 5 will conclude the thesis.
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2. The TCG Singapore Operations
2.1 Products
The complete TCG Operations and the planning process revolve around the different
products that they produce, and hence it would be most appropriate at this point of time
to study the complete product structure at TCG.
The Pharmaceutical Facility I produces a primary finished good, Product A, which is
classified into different types based on the strength or the composition of the main raw
materials used for its production.
Table 1 gives a complete product family view and the production status of the different
finished goods.
Product A Batch Size 750 kg
Composition Strength Part No. Production Status
3WWW Discontinued
Raw Material 4/Product C Tablet W 3WWWB Discontinued
3WWWC In Production
3XXX Discontinued
Raw Material 4/Product C Tablet X 3XXXB Discontinued
3XXXC In Production
3YYY Discontinued
Raw Material 4/Product C Tablet Y 3YYYB Discontinued from September 07
3YYYC In Production
3ZZZ Discontinued
Raw Material 4/Product C Tablet Z 3ZZZB Discontinued from October 07
3ZZZC In Production
Table 1: Current TCG products and their production status
As the table suggests, the four different types of Product A based on the relative strength
of Product C used in its manufacture are characterized as Tablet W, Tablet X, Tablet Y
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and Tablet Z. Tablet W has the lowest strength of Product C while tablet Z has the
highest strength of Product C. Further, each of these strengths is also classified into three
different part numbers. This classification is based on the market that each type can serve.
TCG procures Raw Material 1, a raw material used for the production of Product C, from
different sources. The reason for this is that the different markets for Product A have
approved only specific sources of Raw Material I to be used for Product C/Product A.
Hence TCG needs to classify the different strengths of Product A into different types
again because of the customers' differential approval of the raw material sources. In
Table 2 we show each strength and its raw material sources and the customers/markets
that can be served using that type/ part number.
Strength Part No. Raw Material I Source Customers
Tablet W 3WWWB
Tablet X 3XXXB P3 Europe and NA
Tablet Y 3YYYB
Tablet Z 3ZZZB
Tablet W 3WWWC Latin America and Asia Pacific (Can
Tablet X 3XXXC P2 be shipped to Europe and NA if
Tablet Y 3YYYC quantities of product type B do not
Tablet Z 3ZZZC meet the demand)
Table 2: Finished Products differentiation and respective markets
These products and their classification reflect the current picture of the supply chain at
TCG. We note that Product A is currently produced in a batch size of 750 kg and that
Product A type B will be discontinued in fall 2007 completely. The markets that currently
consume the type B would be served using the new types D and E, the description of
which follows. TCG is currently converting from a batch size of 750 kg to a batch size of
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950 kg and the production validation for the 950 kg batch size is in progress. Starting
from the end of year 2007, most of the demand will be served using the 950 kg batch size
and hence TCG has an additional classification for Product A produced in batch size 950
kg. The Product A tablet W will only be produced in 750 kg batch size, while the other
strengths (tablet X, tablet Y and tablet Z) will be produced in 950 kg batches.
Table 3 shows the new product names and their respective customers.
Product A Batch size 950 kg
Strength Part No. Raw Material 1 Source Customers
Tablet X 3XXXD
Tablet Y 3YYYD P2 Europe and NA
Tablet Z 3ZZZD
Tablet X 3XXXE
Tablet Y 3YYYE P4 NA
Tablet Z 3ZZZE I
Table 3: New Product A Types - differentiation and respective markets
The API facility produces two main products. These are Product C and Product D.
Product D is an intermediate chemical product for some other TCG products and it is
completely produced for other TCG sister sites. The production of Product C is partly
used by Pharmaceutical Facility 1 as an active product ingredient for Product A and is
partly shipped to other TCG sister sites to be used as an active product ingredient there.
The Pharmaceutical Facility 2 will produce a product named Product Bx. This product is
also classified in four different strengths based on the relative amount of Product C used
in this product. These products are Product B, Product Bi, Product B2, and Product B3.
Pharmaceutical Facility 2 is currently producing Product B for clinical trials and TCG
expects to start regular production of this product in the month of December 2007. The
16
trial runs for family Product B would start in the year 2008 and the regular production is
expected to start in the year 2009.
2.2 The Production Facilities and the Supply Chain studied
As mentioned earlier, there are three production facilities at TCG. These facilities share a
common warehouse where the raw materials, packaging materials, intermediate products
and the finished goods are stored. Since the aim of the internship is to reduce the space
requirement for storing these inventories, it becomes important for us to understand how
these facilities interact with the warehouse. The supply chain that we focused on during
the period of the internship can be laid out approximately as shown in Figure 1.
Demand from
Pharmaceutical Facility 1
Raw Material Orders External Demand
API
Suppliers Warehouse Shipment * Customers
Pharmaceutical
Facility I
Raw Material Orders Demand
Figure 1: Supply chain diagram
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There are several reasons why we focussed on this supply chain. Most important,
reducing the space required to store the inventories was management's top most concern.
Second, we limit the project scope to the warehouse inventories as we only focussed on
the processes immediately upstream and downstream of the warehouse. The management
also believed that they are holding too much raw materials and finished goods inventories.
During one of our interviews with Charles Shank, API/Warehouse Operations Director,
he said, " We are not in the warehousing business, we produce medicines". So it was
clear that the management had realized the importance of reducing the inventory and they
want to hold only what is necessary. There are several things one can look at when trying
to implement the lean concepts and reduce inventories. The changeover times between
different products could be studied and reduced, one can have a better information
sharing with the suppliers of the raw materials so that they are prepared to supply only
what is required and when it is required, the process flows could be studied and improved
by improving the scheduling and other parameters, production reliabilities could be
improved to shorten to replenishment lead times and so on. But it was important for us to
focus on the area the management was most interested in.
2.2.1 The Pharmaceutical Facility 1
The Pharmaceutical Facility 1 process is a very traditional mechanical process line
consisting of granulators, drying machines, milling and conveying, blending and finally
compression. Before giving a detailed description about Pharmaceutical Facility 1, it is
important to explain a few terms that I will use.
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i.b.c.: IBC stands for Intermediate Bulk Container. These are the steel vessels that are
used to store the WIP from the start of SPF production till the end.
cycle time: Cycle time is defined as the total time a batch of product spends in the
production facility before it is released as a finished good.
production time: Production time is the time a machine actually needs to process one
batch of a product.
lead time: Lead time is the time from the point an order is issued for a raw material until
the time that the order actually arrives at the warehouse plus the time that it takes for
quality assurance to certify the raw material as good for use.
replenishment lead time: Replenishment lead time is the time it takes to produce a
quantity of a given product in the manufacturing facility. In other words, it is the time
from a batch being initially issued for production until the time that it comes out of the
production facility as a finished good ready to be shipped.
Pharmaceutical Facility 1 can currently produce 25 batches of Product A in 750 kg batch
sizes in each week or 21 batches of Product A in 950 kg batch sizes in each week. These
numbers include the amount of downtime, and the changeover time between different
products. The cycle time for each batch to complete processing is measured to be around
seven to eight days with some variability.
Figure 2 shows a pictorial diagram of the process flow at Pharmaceutical Facility 1.
In the figure, the granulation machine together with the drying machine, the milling
machine and the conveyor is known as the High Shear Module (HSM).
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1- DISPENSING
Raw M aterials (Solvents) R mateENa4 ~Raw materials
(Powders)
2 - CHARGING
3 - SOLUTION PREPARATION
600 L IBC
4 - GRANULATION
High Shear Granulator
5 - DRYING Milling
Pneumatic Conveying I Pneumatic Conveying
7 - BLENDING AND LUBRICATION
8 - COMPRESSION
Figure 2: Pharmaceutical Facility I production facility
This cycle time is the average cycle time measured over a week. This time includes the
time a batch spends in production and the time the batch is waiting for a machine
(queuing time). This is because, the HSM takes the longest time to produce a batch and
material waits before being processed by the HSM. There is also queuing at the
compression machine, where there is limited capacity. There are dedicated compression
machines for tablet X and tablet Y while the other two strengths namely, tablet W and
tablet Z share the same compression machine. Each batch also has to be tested for quality
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after it is released from the last production step, compression. Quality testing takes from
one week to two weeks to finish and after that the material is released for shipment.
2.2.2 The API Facility
The API facility produces three products; Product A Intermediate 3, Product D
Intermediate 1 and Product D Intermediate 3. These three products are manufactured on
two production lines known as Train 1 and Train 2. Train 1 produces the Work-In-
Process (WIP); Product A Intermediate I and Product D Intermediate 1/2 from Raw
Material 1 and Raw Material 2 respectively. The shared equipment between the processes
of producing Product A Intermediate 1 and Product D Intermediate I is shown below.
Production planning for Train I has to take into account the fact that the changeover
between Product C and Product D takes two weeks for cleaning.
In Train 2, the Product A Intermediate 1 is further processed to produce Product A
Intermediate 3. The train B also has a milling line where both Product A Intermediate 3
and Product D Intermediate 3 are produced, each on dedicated equipment.
The product flow through the API facility is shown in Figure 3.
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Trai
Raw Material 4 Product A
Intermediate 1
Raw Material 2 Product D
Intermediate 1/2
/
Figure 3: API production facility
A single batch of Product A Intermediate 3 requires three batches of Product A
Intermediate 2 or one and one half batches of Product A Intermediate 1.
2.3 Customer Demand Forecasting
TCG produces Product A in a joint venture with one of its partner companies. This joint
venture company is responsible for forecasting the demand for Product A. Each month
TCG receives from the JV company a forecast for Product A, over the next two years.
TCG also receives a forecasted monthly demand data for the next two years from another
partner group for Product C and Product D. These forecasts are for monthly periods for
the next twenty four months and are updated each month with adjustments based on the
last month's sales and predicted market behaviors. Such forecasts are used for production
planning and other planning purposes. For the production planning, planners use the
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Train 2
Product A
Intermediate 2
Product A
Intermediate 2
Product A
Intermediate 2
Train 2 (Milling)
Product A
Intermediate 3
Train 1 (Milling)
Product D) Intermediate 3.
forecast of demand two months ahead of today. That is to say, the production planning
for May would be done based on the forecast of the demand for the month of July.
According to the planning team at TCG, at any point of time the forecast for the next
three months is fixed and corresponds to the actual customer orders for the next three
months. This is because they start receiving the actual sales orders three months in
advance.
2.4 The ERP and the Planning Activities
TCG manages its raw materials orders, inventory information, bill of materials and
financial reporting using MRP II. We mainly focused on the use of the system for the
supply chain that we described earlier. That brings us down to the use of the system for
the planning of the raw materials, maintaining bill of materials and managing the
movement of inventories inside their production facilities.
After receiving the forecasts for the demand of Product A, the planning team works out a
Master Production Schedule (MPS) for Pharmaceutical Facility 1, which spans over the
whole year and is adjusted as the forecast changes each month. This MPS is fed to the
MRP system, which generates the requirements for the raw materials and the Active
Product Ingredients from the API facility. The MRP system holds the information on the
different parameters about each raw material like the safety stock, minimum order
quantity, inventory on hand, planned lead time, inspection time etc. Based on the
requirements of the raw materials generated by the MPS for Pharmaceutical Facility 1,
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the planners place the orders for the raw materials required by the Pharmaceutical
Facility 1 from the suppliers.
Based on the Pharmaceutical Facility 1 MPS and the forecasted demand from other
customers, the planners also generate the MPS for the API facility. The MRP system
hence, produces the requirements for the raw materials required by the API facility and
based on these and the other considerations, orders are released for the procurement of
these raw materials as well.
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3. Finished Goods Inventory
3.1 The Approach
In the year 2005, TCG launched what is known as the "TCG Production System". This
was the result of the company's vision towards implementing the famous "Lean
Manufacturing" concepts within its organization. Under this Lean initiative two programs
were targeted. These are a Six Sigma Program and a Lean Program.
The Six Sigma Program targets to reduce the process variability through green belt and
black belt projects. Under the Lean Program, TCG hired a "Sensei" from Toyota and
many lean experts at different sites. These lean practitioners then tried to implement
different ways to remove various wastes. The "TCG Production System" formed the
launch pad for the Lean program. The TCG Production System is based on the famous
"Toyota Production System" and modifies the concepts to suit the pharmaceutical
industry and the TCG operations. The TCG Production System provides two different
guidelines for TCG. One is aimed at elimination of different wastes and the other is
aimed at the organizational level training and change management implementation.
The seven wastes that TCG Production System focuses on are:
o Waste of overproduction
o Waste of waiting
o Waste of transportation
o Waste of inappropriate processing
o Inventory waste
o Waste of excess motion
o Waste from defects
25
We note that it is not only important to eliminate a waste like inventory, but most
important is to find a sustainable way to implement such a change.
I followed the six sigma methodology in my project as that gave me an opportunity to
learn how Six Sigma can be applied in real situations and at the same time it helped to
keep the project aligned with the TCG's Lean program.
3.2 Finished Goods Inventory Trends
For my analysis I only consider the finished goods which are produced by
Pharmaceutical Facility 1. TCG only produces Product A at Pharmaceutical Facility 1
and the product classification has been given earlier. First of all it was important to know
the past trend of the inventory. So we collected the complete inventory data for the past
one and a half year. Figure 4 shows the percentage distribution of inventory space for
finished goods, work in progress, the raw materials, and the packaging materials for a
period from January 2006 until May 2007. We note that by work in progress (WIP), we
mean those materials which are stored in the warehouse after a processing step until the
next processing step, which depends on the production schedule. Hence it should not be
confused with the WIP which is inventory on the shop floor between two production
steps waiting to be processed. This is because the aim of the internship was to reduce the
space requirements of the warehouse and hence we focused only on those materials
which are stored in the warehouse.
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Figure 4: Inventory distribution history
Figure 5 shows the percentage distribution of inventory space between the finished goods,
work in progress, the raw materials, and the packaging materials calculated by taking the
average inventory levels for each type of inventory over a period from January 2006 until
May 2007.
Distribution of Inventory
19% 18%
21%(
* Packaging
" RM
E WIP
Q FG
Figure 5: Percentage distribution of the different inventory categories
Hence we can see that on an average the finished goods contribute as much as 19% of the
total inventory space in the warehouse. I was also interested in finding out why the
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finished goods (hereafter referred to as FG) inventory was considered high by the
management. For this reason I tried to find out the number of weeks that the FGs wait
inside the warehouse before they are shipped to the customer. Table 5 shows the cycle
times for batches for the three different stages of Product A. The three cycle times in the
table are for manufacturing, quality testing and shipment. All the cycle times are in days.
For each month, the table shows the average and standard deviation for the cycle time
data. We see that the variation in the cycle times in the manufacture and quality release is
not very high as compared to the variation in the shipment time. For example, in the
month of January, 2007, the average time that a batch spent in the warehouse waiting to
be shipped was 24.9 days with a standard deviation of 11.3 days.
Cycle Times for Product A (in days)
Month Data ProducA Mayufacture d A rduct A Relea etoRelease Shipmeent
mean 7.1 17.4 24.9
Jan-07 std 1.7 6.2 11.3
CV 0.2 0.4 0.5
mean 8.1 8.3 17.0
Feb-07 std 3.2 4.4 12.0
CV 0.4 0.5 0.7
mean 8.9 7.9 20.0
Mar-07 std 2.1 4.3 11.0
CV 0.2 0.5 0.6
mean 5.4 9.6 16.9
Apr-07 std 1.1 2.2 11.6
CV 0.2 0.2 0.7
mean NA NA 35.1
May-07 std NA NA 26.1
CV NA NA 0.7
Table 4: Cycle times for three stages of Product A supply chain
There is also another reason why FG inventory levels are on the higher side. TCG also
plans to run the production validation for Product B in the near future. To do this requires
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that Pharmaceutical Facility 1 stops the production of Product A for that period of time
because the production of Product Bx shares the HSM with Pharmaceutical Facility 1.
One of these validation runs is planned in the month of November 2007 and hence the
current high levels could be attributed to the over production of Product A to meet the
demand of Product A during November 2007.
Figure 6 shows the month end inventory data for the different FGs that are stored in the
warehouse from January 2006 to May 2007.
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Figure 6: Historical inventory trend by product
Before proceeding ahead, I will discuss the general reasons why one would like to keep
FG inventory stock in the warehouse. There are several factors which affect the decisions
why stocks are maintained such as:
Uncertainty: The uncertainties may be in production, demand, testing, lead times and in
transportation. One reason that people tend to keep inventory is uncertainty in supply or
in demand or both. It is impossible to tell the future and the future prediction is done
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based on the past data using forecasting. Also forecasts are never accurate and hence the
demand can never be predicted with 100% accuracy. Production machines are never
100% reliable and neither is the transportation nor the lead times.
Production Constraints: The Production might be such that the factory does not produce
one product continuously and hence they have to maintain the inventory of such products
for the period of the time it is not produced. The defect rate could be high and random.
The production capacity also drives the inventory levels. If one has unlimited capacity
and enough money to invest, it is possible to have zero inventory levels also.
Though all these issues may not exist at TCG, but still there can be significant inventory
inside the warehouse just because of any of these alone.
3.2.1 Planning for Pharmaceutical Facility 1 Production
During my data collection phase and a number of interviews with different people inside
the company, I realized that the production operation at Pharmaceutical Facility 1 is very
reliable with minimal variation. I will further show the data to support this claim. From
my observations and the data collected, the production planning operation can be
described as follows:
I. The demand for each product is received from the JV company by the planners.
2. The production is planned in a way so that the orders for the second month from
now are put in production in the current month. For example, the production to
meet the demand for the month of March starts somewhere in the month of
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January. There does not seem to be a good reason to do this, other than the
conservativeness of the planning and the result of this is excess FG inventory.
3. The rough cut production capacity of Pharmaceutical Facility 1 is 25 batches (750
kg) of the finished goods every week. Since the products differ in their strength,
there is an equipment cleaning activity when switching from one strength to
another. TCG has minimized this cleaning time and simplified the process so that
only dry cleaning of the equipment is needed during the changeover from one
strength to another. To achieve this, the production sequence follows a cyclic
repeating pattern.
3WWW Step Increase in3XXX Strength
Production
3ZZZ-
Sequence 3Z3YYY jStep Decrease in
3XXX trength
3WWW Fl
3XXX Step Increase in
Strength
Figure 7: Production sequence for different Product A strengths
This sequence is followed at all times in the production. The reason for this is that
if TCG plans to change from a strength of say tablet Z to tablet W, then the
cleaning activity required would be very time consuming.
4. There is no cleanup activity carried out between the production of two different
types of products of the same strength. That means Pharmaceutical Facility I can
switch from 3WWWB to 3WWWC without any stoppage for cleanup.
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5. There are four compression machines at Pharmaceutical Facility 1. Currently only
three machines are used for the production of Product A and the fourth machine is
used for the trial production of Product Bx family.
The whole planning process that I described above applies to the current situation at TCG.
As I mentioned above, in December 2007 TCG will start the production of a new product
at Pharmaceutical Facility 2 named Product B. This product will be produced at
Pharmaceutical Facility 2, but the HSM at Pharmaceutical Facility I will be shared
between the Product A family and the Product B.
3.3 The Customer Demand and the Forecast Accuracy
The MPS and MRP from Data3 are based on the forecasted customer demand. Making
these production and inventory decisions as if the projected data is accurate will result
either in stock out if the true demand is higher than projected or high inventory levels if
the true demand is over-projected. Therefore, we calculated the accuracy of the forecast
data to determine how confident we are that the production and inventory decisions we
make using the data meet the actual demands.
The monthly forecasted demands for each product for the next 2 years are updated every
month, close to the end of each month. Therefore, the true demand for a certain month is
obtained only from the data sent out in the following month.
To calculate the forecast accuracy, let f; (t + i) be the forecast made at time t for the
customer demand for finished products in period t + i, where i = 1, 2, ... 24 months. The
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actual demand observed in period t is denoted byf (t), the forecast made in period t for
the demand in period t. There is no information beyond the forecast horizon of 2 years.
Every month, an updated set of forecasts f (t + i) will be generated and we define the
updates of the forecasts from month to month by the forecast revision, Af (t + i):
Af, (t +i)= ft(t +i) - f,_,(t +i)
We then measured the i-th period forecast error as the difference between the actual
demand in period t and the forecast of this demand made i periods earlier:
ft (t) - f_ (t)= Af (t) + Af_, (t) +K + Af1 _,1 (t),
where Af (t)= f (t) - f-I (t).
To assess how each forecast revision improves the forecast, we calculated the variance of
the i-th period forecast error by using:
Var[f (t) - f_1 (t)]= Var(Af, (t)) + Var(Af (t)) +...+ Var(Af _,+ (t))
Where, we assume that the forecast revisions are independent over time and thus we can
add the variances.
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The projected forecasts for the demands of all 12 types of Product A in the months of Feb
2007, Mar 2007 and Apr 2007 are tabulated against the month when the forecasts are
made. The figures 8, 9 and 10 show how the forecasts for each product change from more
than a year ago to the delivery months of Feb 2007, Mar 2007 and Apr 2007 respectively.
The products "3WWW" and "3ZZZ" are not included in the graphs because there is no
demand for them in the 3 delivery months.
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Figure 8: Forecast projection history for February 2007
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Figure 10: Forecast projection history for April 2007
35
Projection History for Mar'07
-4-3WWVVB
90000 3wIC
' 80000 x
-4-3XXXB7 0000
4I0-- 3XXX
C 30000
4-- 3YYYB
20000
n. 10000 -......... 3YYY C
0
--- 3ZZZB
S-0 x3ZZZC
Projection History for Apr'07
-.- 3WNwE
90000 3XXXB
o 0000
7 0000-7
60000 - 3XXXB
E50000 wx
40000
lv 3YYY30000
S20000 -- 3YYYB
LL. 10000- YY
0
-U- 3ZZZB
e A 3ZZZC
The figures 8, 9 and 10 show that product 3XXXC (topmost curve) has the highest
projected forecast demands in all 3 shipment months, followed by product 3YYYC
(second curve from top). 3WWWC (third curve) and 3ZZZC (fourth curve) have almost
similar projected demands but are lower than that of 3YYYC. The rest of the products
have the least projected demands.
The graphs also show rather flat trends which indicate that the forecast for Product A is
quite accurate. While TCG keeps a certain level of safety stock for API, they adopt a
make-to-order policy for Product A. In the case where a customer increases his order of
Product A within the 3-month lead time, TCG may give the customer a portion of another
customer's demand for the same product. This is provided that the quantity is not too
large and the customer who has given up the portion of the finished product is
compensated with a similar product of the same strength.
Customers also prefer to receive another Product A type of the same strength but with
raw material from a different supplier rather than receive another Product A of different
strength but with the same raw material source. Therefore, a more accurate way of
characterizing the forecast error for the demand of Product A may be to aggregate the
forecast demands for all products of equal strength. There are 4 different strengths of
Product A: tablet W, tablet X, tablet Y and tablet Z. The graphs below show the forecast
histories of the aggregated demands for Product A of the same strength, for the months of
February 2007, March 2007 and April 2007.
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Figure 11: Forecast projection history for February 07 for different strengths of
Product A
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Figure 12: Forecast projection history for March 2007 for different strengths of
Product A
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Figure 13: Forecast projection history for April 2007 for different strengths of
Product A
The figures 11, 12 and 13 show that Product A tablet X (topmost curve) have the highest
aggregated projected demands in all the 3 shipment months, followed by products tablet
Y (second curve from top). Products tablet W and tablet Z have the least projected
demands.
We observe that the forecast accuracy does not seem to have improved from the
previously non-aggregated case. Therefore, we need to compare the results from the
calculated values of the forecast errors for both non-aggregated and aggregated demands
to find out if there is really no improvement.
To find the forecast errors for the non-aggregated demands, we first calculated Af (t), the
forecast error for period i=O, which is the difference between the forecast one month
before shipment and the actual demand for each of the products for each of the 3 delivery
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months (Feb 2007, Mar 2007 and Apr 2007). We then calculated rn , the variance of the
30 forecast error values that we obtained from the 10 products in the 3 delivery months
studied. The variance of forecast error for the one-month ahead forecast is equal to (-0.
We calculated the variance of forecast error for the 2-month ahead forecast by adding the
variance of the forecast errors in the 2 "d month before delivery, o7 , to the previous value
of cr . We continued calculating the variance of the n-month ahead forecast error for n =
1, 2, ... 12, based on the 30 observations for each period. We plot the variances of these
forecast error for all the periods in Figure 14.
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Figure 14: Variance of forecast error for Pharmaceutical Facility 1 - Non
Aggregated
The projection of variance of the forecast error for the non-aggregated forecast demands
show that variance changes very little for 12 months before shipment and there is a
significant drop in variance in the 5-month period before shipment.
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Next, we find the forecast errors for the aggregated demands by first aggregating the
monthly forecast data for the products tablet W, tablet X, tablet Y and tablet Z. We then
used the 12 forecast error values that we obtained from the 4 aggregated products in the 3
delivery months studied to calculate the variance of each of the n-month ahead forecast
error for n = 1, 2, ... 12. We plot the variances of these forecast error for all the periods in
Figure 15.
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Figure 15: Variance of forecast error for Pharmaceutical Facility 1 - Aggregated
The projection of variance of the forecast error for the aggregated forecast demands show
that variance changes very little 12 months before shipment and there is a significant drop
in variance in the 5-month period before shipment. This observation is similar to what we
observed in Figure 14 for the non-aggregated forecast demands.
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To make a fair comparison between the forecast errors for the non-aggregated forecast
and aggregated forecast, we compared their coefficients of variation (CV) for each n-
month ahead of forecast in Figure 16. The coefficient of variation is calculated as:
V = SD Var[ f (t)-f_(t)] 2 2 2CV= forecast error + co~ +O . . .+O
x x x
where x is the average of forecasts in the n month.
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Figure 16: Projection of the CV of the Forecast Error for Pharmaceutical Facility 1
The graph shows that for every period, the CV of the forecast error is lower when the
forecasts are aggregated. Therefore, by aggregating the forecasts, we reduce the variance
of the forecast error; this is a form of risk pooling. That is, on average there is some
cancellation of the variability of the demand of the individual products; if one product has
a forecast that is too high, then there might be another product with a forecast that is too
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low, and hence the errors will cancel each other. We expect this to happen as long as the
product demands are not positively correlated with each other. Therefore, we should get a
more accurate result if we use the aggregated data for all analysis.
Overall, all graphs show small changes in the CV from the 1-month to the 12-month
period, with the CV values kept below one. This suggests that the forecast within the 12-
month period is fairly accurate. Beyond the 12-month period, the CV increases sharply
beyond the value of one, indicating the forecast error is quite large. Therefore, we should
be comfortable in using the forecast data for the demand in the next 12 months for all our
analysis.
3.4 Future Changes
Currently the production is straight forward with Pharmaceutical Facility 1 serving as a
dedicated line for the production of Product A family with zero time loss during the
changeover from one raw material source to another and a very small clean up time
during the changeover between two different strengths. Starting in December, TCG will
produce Product B at the Pharmaceutical Facility 2 facility. But this product shares the
High Shear Module with the production of Product A at Pharmaceutical Facility 1.
In lieu of this, TCG plans to change their production planning from the current to a
campaigning production because of a significant changeover time between the two
product families.
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3.4.1 Forecast for Product B
The forecast for Product B is available and the data is shown in the Table 6 below:
Monthly forecasted demand for Product B for the year 2008
Month Jan Feb Mar pr May Jun Jul Aug Sep Oct Nov Dec Total
No. of Batches 23 26 26 15 16 15 18 25 37 32 34 37 304
Table 5: Product B demand forecast for the year 2008
Hence the total number of batches of Product B for the whole year is 304. Since Product
B and Product A share the HSM module at Pharmaceutical Facility 1, the total annual
demand for Product A cannot be met. TCG has decided to shift some portion of the
Product A production to another TCG production facility. As per the decision, TCG plans
to make only 460 batches of Product A (950 kg equivalent) in the year 2008.
However, I do not know how this total demand will be spread over the year at
Pharmaceutical Facility 1. Hence from this point forward, I will assume the total demand
of Product A to be evenly distributed over the 12 month period.
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4. Production scheduling and Inventory calculations
As I explained in the Chapter 2 and Chapter 3, Pharmaceutical Facility I currently
produces one main FG that is Product A and starting in December, HSM at
Pharmaceutical Facility 1 will be shared between two products; Product A and Product B.
There is a significant changeover time (3 days) between the two products and for this
reason the HSM at Pharmaceutical Facility 1 will run the production of these two
products in lots (campaigns). But these campaigns should be planned in a way to have the
minimum inventory levels with a high customer service level.
The problem at Pharmaceutical Facility 1 is to find the optimum production lots to meet
the demand of each product keeping the inventories as low as possible. I will try to use a
single-stage two part type model as a base to determine the optimum production
campaign lengths.
4.1 Campaign Production Model
The HSM at Pharmaceutical Facility I is shared between Product A and Product B; the
total production capacity at Pharmaceutical Facility 1 depends only on the production
capacity at HSM because HSM is the bottleneck in case of the shared production. For this
reason, I plan to model only the HSM. We can model the HSM module at Pharmaceutical
Facility 1 as a single-stage two part type system. I consider two part types because I take
Product B as one part and Product A as the other part.
Figure 17 illustrates a typical production cycle for two products using single-stage two
part type model. The figure shows the cumulative demand lines for the two products and
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their respective cumulative production curves. In order to avoid a stock out, the
production for a product must start when its cumulative production line hits the
cumulative demand line; the setup for the product must be completed just prior to this
point, and in the minimal length cycle, the setup for a product begins immediately after
the production of the other product ends.
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Figure 17: Production campaigning model for two product types
I consider Product A as product 1 and Product B as product 2. I define the Cycle Time to
be the time to complete one Product A production campaign, plus the setup time after the
Product A campaign is over, plus the production time for one Product B production
campaign, plus the setup time after Product B production. The key inputs for the model
are the demand rates of the two products, the unit production times for the two products
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and the setup times for the two products. We need to determine the minimal Cycle Time
such that the production of one campaign for each product meets the total demand for
that product over the whole cycle.
If 'T' is the length of the cycle, then
S1 +r 1Q1+ S,+ ,Q,= T
Where,
di is the demand rate for product i during a campaign
Q is the quantity produced for product i during a campaign
Ti is the production time to produce one unit of product i
Si is the setup time for product i
To satisfy the demand, we have
Q, =d T
Using the above two equations we get,
S,+ TT +S,+ + dT =T
and hence,
T =r+d 2
I1-(rid, + r,)
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rd, is the fraction of time that is devoted to the production of part i and 1- (rd, + z2d2 )
is the fraction of time that is not devoted to production but is available for setups. Hence
the feasibility condition becomes rid, + rd 2 <1
The model requires the following assumptions:
" The demand is deterministic and occurs at a constant rate.
" The setup times are deterministic.
* The production times are deterministic.
As mentioned before, the production times can be considered deterministic as the HSM is
capable of producing a fixed number of batches every week. The setup times are treated
as deterministic. Since the actual demand is not constant and deterministic, it is important
to keep additional safety stock to deal with the monthly variation in the demand.
4.1.1 Model Setup
From the campaigning model that I described in section 4.1, I generated various scenarios
to find out the FG inventory levels. It is possible to have a large number of scenarios but I
will only present a few most important ones to show how the campaigning model can be
used to schedule the production and reduce the inventories. Table 7 shows the summary
of the Scenarios that follow.
Annual Demand Demand Rate Remarks
Product B Product A Product B Product A
Based on actual mean of the Evenly Generated to model the
Scenario 1 304 460 demand distribution for the distributed over actual situation at TCG
two halves of the year 12 months in 2008 (MPS is not yet
Scenario II 304 460 Based on the total annual Evenly generated by TCG for
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demand of 304 batches
evenly distributed over the
12 month period to produce
equally in each half of the
year
distributed over the change in demand
12 months of Product A)
Based on actual mean of the Evenly
Scenario fIt 304 475 demand distribution for the distributed over
two halves of the year 12 months Generated forBased on the total annual comparison with thedemand of 304 batches Evenly MPS generated by TCG
Scenario TV 304 475 evenly distributed over the distributed over for the year 200812 month period to produce 12 months
equal in each half of the
year
Table 6: Summary of the various Scenarios generated using the Single Stage Two
Product Model
Scenario I
I modeled the campaigns for the first six months of 2008 and the last six months of 2008
separately. This is because the production capacity of Product B will increase from 19
batches per week to 22 batches per week starting in the month of July 2008.
According to the latest decisions, TCG plans to produce 460 batches of Product A (950
kg equivalent) in the year 2008. The demand data for the first six months for the two
products is shown in Table 8.
Product A Product B
(batches) (batches)
Jan'08 38.3 23
Feb'08 38.3 26
Mar'08 38.3 26
Apr'08 38.3 15
May'08 38.3 16
Jun'08 38.3 15
Total 230 121
Table 7: Demand data for first six months for Scenario I
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In the month of June, there is a planned downtime in the Pharmaceutical Facility 1
facility for the production validation of Product B for three weeks.
Hence, the number of weeks available for production during the first six months is 23.
The weekly demand (demand rate) for Product A, d, = 230 /23=10 batches / week
The weekly demand (demand rate) for Product B, d2 =121/ 23=5.26 batches / week
The setup time post Product A production, S, = 3 days = 0.429 = weeks
The setup time post Product B production, S2 = 3 days = 0.429 = weeks
Table 9 summarizes the model parameters and the values for the two products for the first
six months of Scenario 1.
Unit ProductionSetup Times, Production Rate im P Demand Rate, di
Si (weeks) (batches/week) Time, r, (batches/week)(week/batch)
Product A 0.429 22 0.04545 10
Product B 0.429 19 0.0526 5.26
Table 8: Model inputs for first six months for Scenario I
Table 10 shows the excel spreadsheet model calculations for the above.
ti 0.0455 Weeks
dl 10 batches/week
Model t2 0.0526 Weeks
inputs d2 5.26 batches/week
s1 0.4286 eeks
s2 0.4286 eeks
T 3.4188 eeks
Model Q1 34.188 Batches
Outputs Q2 19.145 Batches
P1 1.554 eeks
P2 1.0076 eeks
Table 9: Cycle length Calculation for first six months for Scenario I
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where, P1 is the length of Product A campaign and,
P2 is the length of Product B campaign
Hence we find that the cycle length 'T' is 3.418 weeks and the number of batches
produced for Product A is 34 batches in each cycle and that for Product B is 19 batches.
The demand data for the last six months for the two products is shown in Table 11.
Product A Product B
(batches) (batches)
Jul'08 38.3 18
Aug'08 38.3 25
Sep'08 38.3 37
Oct'08 38.3 32
Nov'08 38.3 34
Dec'08 38.3 37
Total 230 183
Table 10: Demand data for last six months for Scenario I
In the month of September, there is a planned downtime in the Pharmaceutical Facility I
facility for the production validation of Product B for four weeks.
Hence, the number of weeks available for production during the last six months is 22.
The weekly demand (demand rate) for Product A, d, = 230 /22 =10.45 batches / week
The weekly demand (demand rate) for Product B, d2 =183 / 22 =8.3 batches / week
The setup time post Product A production, S, = 3 days = 0.429 =weeks
The setup time post Product B production, S2 =3 days =0.429 = weeks
Table 12 summarizes the model parameters and the values for the two products for the
last six months of Scenario I.
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Unit ProductionSetup Times, Production Rate im i Demand Rate, di
Si (weeks) (batches/week) Time, r (batches/week)(week/batch)
Product A 0.429 22 0.04545 10.5
Product B 0.429 22 0.04545 8.3
Table 11: Model inputs for last six months for Scenario I
Table 13 shows the excel spreadsheet model calculations for the above.
t1 0.0455 eeks
d1l 10.5 atches/week
Model t2 0.0455 eeks
Inputs d2 8.3 batches/week
s1 0.4286 Weeks
s2 0.4286 Weeks
T 5.893 Weeks
Model Q1 61.875 Batches
Outputs Q2 48.911 Batches
P1 2.8125 Weeks
P2 2.2232 Weeks
Table 12: Cycle length Calculation for last six months for Scenario I
where, P1 is the length of Product A campaign and,
P2 is the length of Product B campaign
Hence we find that the cycle length 'T' is 5.893 weeks and the number of batches
produced for Product A is 62 batches in each cycle and that for Product B is 49 batches.
I generated an MPS based on scenario I and it is shown in Table 14.
January February Macrh A ril
Week 7 14 21 28 4 11 18 25 3 10 17 24 31 7 14 21128
Product A in 950 kg
units 22.012.2 2.6 22.0 3.0 22.0 9.2 15.7 18.5 6.5 22.0 5.7
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Product B Wkly
otal 1 0.3 19.0 1 10.9 8.3 12.9 16.2 1 13.9|5.2 15.9113.2
May June July Au ust
Week 5 12 19 26 2 9 16123130 7 14 21 28 4 11 18 25
Product__ in_950 kg unit s8.15.3 9.3 22.0 2.9 Fonie2.022.020.5 0.0 20.422.0
Product B Wky Total 16.32.9 8.3 14.1 2.014.3
September October November December
Week I 181 15 122 29 6 13 20 27 3 10 17 24 1 8 15 22 29
Product A in 950 kg units Downtime 12 19 22 22 1.6 17 22
Product B Wkly Total 11322 15.9 0 11 22 18 0 16 14
Table 13: Master production schedule for Scenario I
According to the MPS generated;
Total annual Product A Production = 462 batches
Total annual Product B Production = 304 batches
Care should be taken while generating the MPS when it reaches the last cycle. For
example, for the last six months of 2008 the cycle time is 5.893 weeks. And hence the
total number of cycles possible are 22/5-893= 3.9. So when the third cycle ends at
Product B production, Product A should be produced during the last cycle only for the
time till the total cumulative production of Product A for the six months equals the
demand for those six month and then Product B should be produced for the remaining of
the year 2008. For the year 2009, based on the forecasts for Product A and Product B,
MPS revisions will be necessary.
Safety Stock Calculations
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The campaigning model that I used for the production scheduling is a deterministic
model and is based on the assumption that the demands are constant and deterministic.
But in fact, the demands are variable and hence a safety stock is required to account for
the variability in the demand. In this case, the two products are produced in a defined
cycle and each time the quantity produced is the same. This situation closely resembles
the Continuous Review Inventory Policy in which the time between the orders varies but
the quantity ordered is fixed. Hence, I used the Continuous Review Policy to calculate the
safety stocks required for each product.
monthly safety stock = z x STD x IL
z = safety factor
STD = std deviation of demand
L = replenishment lead time
I used z = 2, which corresponds to a coverage probability of 0.98. Table 15 shows the
calculated safety stocks for the two FG.
(STD L Safety
(months) Weeks Months Stock
Product A 2 5.775 5.89 1.374 13.5
Product B 2 8.27 5.89 1.374 19.3
Table 14: Calculation of safety stock for Scenario I
The monthly standard deviation for Product B is calculated from the monthly demand
forecast data presented in section 3.4.1.
The standard deviation for Product A is calculated from the old demand forecast of
Product A and it is assumed to be the same for the new demand distribution.
The replenishment lead time is assumed to be equal to the cycle length calculated for the
last six months of 2008 since after each cycle, each product is produced again. I
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considered the cycle length for the last six months to be the replenishment lead time
because the cycle length for the last six months is greater than that for the first six months
and the safety stock needs to cover this larger lead time.
Based on the MPS generated above, the end-of-month inventory levels for the year 2008
are calculated as shown in Table 16.
Batches
On Hand Jan Feb Mar Apr May JunIul Aug Sep Oct Nov Dec
Product B 20 16 9.5 17 26 29 22 18.5 30 -7.1 11.4 10 21
Product A 14 22 30 34 28 133 18 43.3 47 30 9.51 16 16
Pallet Spaces MaxAverage
Product B 220 180 104 182 285 320 246 204 329 0 125 114 230
Product A 56 87 119 137 113 131 71 173 186 119 38 65 66
TOTAL 276 267 223 318 398 451 317 377 515,119,163 178 29515151
Table 15: Monthly FG Inventory distribution for Scenario I
The inventory on hand at the beginning of January is actually the calculated safety stock
levels for each product. From this table we can see that the maximum pallet spaces
required to stock the finished goods in the year 2008 is 434. This number is calculated by
adding the monthly pallet space requirement for each product and then taking the
maximum number over the one year period. The average pallet space inventory over the
year is 264.
We see that the Scenario I results in a stock out of Product B in the month of September
for 7 batches. This stock out is because we assume in the model that the first 22 weeks
are available for production during the last six months of 2008. So the model produces at
a rate to produce extra every month for the first five months to meet the demand during
the last four weeks of downtime. So when I shifted the downtime to September to
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represent the actual situation at TCG, the extra production prior to September is not
sufficient to meet the demand during the downtime.
Figure 18 shows the monthly pallet space distribution for Scenario I.
Inventory Trend for Scenario I
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Figure 18: Monthly pallet space distribution for 2008 for Scenario I
Scenario II
Scenario II is generated to overcome the limitations of Scenario I. We observe in
Scenario I that we get a stock out of one of the products. This is because the demand rates
for the two halves of scenario I are based on the actual demand means for the two halves.
Now since the demand for Product B is low in the first six months, the production is also
low. When the demand increases for the next six months, the production is increased, but
the downtime in September results in stock out. To overcome the stock out I recommend
producing Product B at a rate based on the total annual demand. The total demand for
Product B for the year 2008 is 304 batches. To level the production over the entire year, I
will use the demand rate for Product B during the first six months as 152/23 = 6.6
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batches/week and for the last six months as 152/22 = 6.9 batches/week. Table 17 shows
the data used for the model for the first six months.
Unit ProductionSetup Times, Production Rate im r Demand Rate, di
S, (weeks) (batches/week) Time, r, (batches/week)(week/batch)
Product A 0.429 22 0.04545 10
Product B 0.429 19 0.0526 6.6
Table 16: Model inputs for first six months for Scenario II
Table 18 shows the excel spreadsheet model calculations for the above.
ti 0.045 weeks
dl 10 batches/week
Model t2 0.052 weeks
Inputs d2 6.6 batches/week
s1 0.428 eeks
s2 0.428 eeks
T 4.327 eeks
Model Q1 43.27 batches
Outputs Q2 28.56 batches
P1 1.966 weeks
P2 1.503 eeks
Table 17: Cycle length Calculation for first six months for Scenario II
where, P1 is the length of Product A campaign and,
P2 is the length of Product B campaign
Hence we found out that the cycle length 'T' is 4.327 weeks and the number of batches
produced for Product A is 43 batches in each cycle and that for Product B is 29 batches.
Table 19 summarizes the model parameters and the values for the two products for the
last six months of Scenario I.
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Unit ProductionSetup Times, Production Rate im P Demand Rate, d.
S, (weeks) (batches/week) Time, r (batches/week)(week/batch)
Product A 0.429 22 0.04545 10.5
Product B 0.429 22 0.04545 6.9
Table 18: Model inputs for last six months for Scenario II
Table 20 shows the excel spreadsheet model calculations for the above.
ti 0.0455 weeks
dl 10.5 batches/week
Model t2 0.0455 weeks
Inputs d2 6.9 batches/week
si 0.4286 eeks
s2 0.4286 eeks
T 4.012 weeks
Model Q1 42.12 batches
Outputs Q2 27.28 batches
P1 1.9149 weeks
P2 1.2401 weeks
Table 19: Cycle length Calculation for last six months for Scenario II
I generated the MPS for Scenario II and it is shown in Table 21.
January February March April
Week 71421 28 4 11 18 25310117 24 31 7 14 2128
Product A in 950 kg units 2221 14.1 22 7.13 6.912214.3 2 21.3
Product B Wkly Total 11 17.7 4.7 194.9 7.6 10.9 18
Ma June Jul Au ust
Week 5 12 19 26 2 9 _16123130 7 14 21 28 4 11 18 25
ProductAin950_kg units 14 22 7.1 6.9 6.6 'Downtime 22 20
Product B Wkly Total 4.7 19 4.9 5.7 14 13 14 13
September I October November December
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Week 118115122 29 6 13120 2713 10 1724 1 8 15 22129
Product A in 950 kg unit 22.0 20.1 2220 2220 1
Product B Wkly Total 1412.8 14.5 1 14 3 16
Table 20: Master production schedule for Scenario II
Table 22 shows the calculated safety stocks for the two FG. Here I consider the
replenishment lead time to be equal to the cycle length for the first six months of 2008
since this cycle length is greater of the two cycle lengths calculated for the year.
STD L Safety
Z (months) Weeks Months Stock
Product A 2 5.775 4.327 1.01 11.6
Product 2 8.27 4.327 1.01 16.6
Table 21: Calculation of safety stock for Scenario II
Table 23 shows the calculation of the end-of-month inventory in batches and
corresponding pallet spaces for both products for the year 2008 based on the MPS shown
in Table 21.
Batches
Inventory on Hand JanFe Mar A May un Jul Augse Oct NovDec
Product 17 23120 27.7 41 48.944 3.856.1 46 41.6 135 7
Product A 12 117123 26.8132137.4 12 16 20.2145 49.4 49 112
Pallet Spaces Ma Average
Product B 187 248 223 304 454 53814891592 617 510 458 384 186
Product A 48 69 90 107 128 149 48 p4.180.6181 198 202 46
TOTAL 235 317313 412 582 688 537J656 697 691 656 581 232 697 508
Table 22: Monthly FG Inventory distribution for Scenario II
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We can observe that the Maximum pallet spaces required to store the FGs in the year
2008 based on the Scenario II are 697 and the average pallet space inventory over the
year is 508. The monthly pallet space distribution for the year 2008 is also plotted as
shown in the Figure 19.
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Figure 19: Monthly pallet space distribution for 2008 for Scenario II
We see from Scenario II that there is no stock out of any product in this case and also the
minimum end-of-month inventories are at least equal to two standard deviations of the
demand. Hence the demand variation can be handled well in this case.
4.2 Models for Comparison with current TCG plan
Scenario III
I will now compare the single-stage two product model with the current plan at TCG. I
received an MPS made by planners for the year 2008. This MPS was made prior to the
final decision on the amount of Product A to be shifted away from TCG, Singapore and
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the total demand of Product A for this MPS is considered to be 475 batches for the year
2008.
Hence I generate two new scenarios based on the demands and production rates of two
products. I also assumed the total demand of Product A to be 475 batches evenly
distributed over the 12 month period.
The demand data for the first six months for the two products is shown in Table 24.
Product A Product B
(batches) (batches)
Jan'08 39.6 23
Feb'08 39.6 26
Mar'08 39.6 26
Apr'08 39.6 15
May'08 39.6 16
Jun'08 39.6 15
Total 238 121
Table 23: Demand data for first six months for Scenario III
As mentioned before, there is a planned downtime in the Pharmaceutical Facility I
facility for the production validation of Product B for three weeks. Hence, the number of
weeks available for production during the first six months is 23.
The weekly demand (demand rate) for Product A, di = 238 /23=10.34 batches / week
The weekly demand (demand rate) for Product B, d2 = 121/ 23 = 5.26 batches / week
The setup time post Product A production, S, =3 days =0.429 = weeks
The setup time post Product B production, S, = 3 days = 0.429 = weeks
Table 25 summarizes the model parameters and the values for the two products for the
first six months of Scenario II.
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Unit ProductionSetup Times, Production Rate im P Demand Rate, di
S (weeks) (batches/week) Time, r, (batchestweek)(week/batch)
Product A 0.429 22 0.04545 10.4
Product B 0.429 19 0.0526 5.3
Table 24: Model inputs for first six months for Scenario III
Table 26 shows the excel spreadsheet model calculations for the above.
ti 0.0455 eeks
dl 10.4 batches/week
Model t2 0.0526 eeks
Inputs d2 5.3 batches/week
s1 0.4286 weeks
s2 0.4286 weeks
T 3.50 weeks
Model Q1 37.02 batches
Outputs Q2 19.00 batches
P1 1.696 weeks
P2 1.000 weeks
Table 25: Cycle length Calculation for first six months for Scenario III
where, P1 is the length of Product A campaign and,
P2 is the length of Product B campaign
Hence we see that the cycle length 'T' is 3.5 weeks and the number of batches produced
for Product A is 37 batches in each cycle and that for Product B is 19 batches.
The demand data for the last six months for the two products is shown in Table 27.
Product A Product B
(batches) (batches)
Jul'08 39.6 18
Aug'08 39.6 25
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Oct'08 39.6 32
Nov'08 39.6 34
Dec'08 39.6 37
Total 238 183
Table 26: Demand data for last six months for Scenario III
In the month of September, there is a planned downtime in the Pharmaceutical Facility 1
facility for the production validation of Product B for four weeks.
Hence, the number of weeks available for production during the last six months is 22.
The weekly demand (demand rate) for Product A, d, = 238 /22=10.82 batches / week
The weekly demand (demand rate) for Product B, d2 =183 /22=8.3 batches / week
The setup time post Product A production, S, =3 days =0.429 = weeks
The setup time post Product B production, S2 =3 days =0.429 = weeks
Table 28 summarizes the model parameters and the values for the two products for the
last six months of Scenario II.
Unit ProductionSetup Times, Production Rate im P Demand Rate, di
Si (weeks) (batches/week) Time, r (batches/week)(week/batch)
Product A 0.429 22 0.04545 10.9
Product B 0.429 22 0.04545 8.3
Table 27: Model inputs for last six months for Scenario III
Table 29 shows the excel spreadsheet model calculations for the above.
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39.6 37Sep'08
ti 0.0455 eeks
dl 10.9 atches/week
Model t2 0.0455 eeks
Inputs d2 68.3 batches/week
si 0.429 weeks
s2 0.429 weeks
T 6.778 weeks
Model Q1 73.88 atches
Outputs Q2 56.38 batches
P1 3.358 eeks
P2 2.562 eeks
Table 28: Cycle length Calculation for last six months for Scenario III
The MPS generated based on scenario III is shown in Table 30.
January Februa March April
Week 7 114 21 28 4 Ill 18 25 3 101 17 241 31 7 14 121 28
Product A in 950 kg unit 15.3 9.7 22 5.6 19.5 17.8 7.23 22 8.09 __ 17 20
Product B Wkly Total 16.6 2.4 6 13 14 4.61 3.87 15 12
May June July August
Week 5 12 19 26 2 9 16 23 30 7 14121 28 4 11 1 125
Product A in 950 kg units 4.7 22 10.6 13 Downtime 22 22 22 7.88 - -- 9122
Product B Wkly Total 6.8 1.7 19 19 4.69 22 22 7.
September October November December
Week 1_|8115_ 22 _29 6 13 2027 3 1017 24 1 8152229
Product A in 950 kg units Downtime 22 22 3.01 9.76 22 22 20.1 13 8
Product B Wkly Total j 9.57 22 22 2.82 14.52
Table 29: Master production schedule for Scenario III
According to this MPS,
Total annual Product A Production = 478 batches
Total annual Product B Production = 304 batches
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Table 31 shows the safety stock calculations for Scenario III. I considered the cycle
length for the last six months to be the replenishment lead time because the cycle length
for the last six months is greater than that for the first six months and the safety stock
needs to cover this larger lead time.
STD L Safety
Z (months) Weeks Months Stock
Product A 2 5.775 6.77 1.58 14.5
Product 2 8.27 6.77 1.58 20.8
Table 30: Safety stock calculation for Scenario III
Table 32 shows the monthly inventory calculations for the year 2008 based on the MPS
generated in Table 30 for Scenario III.
Batches
Inventory On Hand anFebMapmay un Jul AuSe Oct No Dec
Product 21 17 10 6.9 19 31 35 21.4 48 11 32.6 1.5 23
Product 15 22 29 44 42 39 11 5.4 32 14 -0.733 16
Pal et Spaces MaxAverage
Product 231 187110 76 211 338 382 235 529 122 359 0 252
Product 60 88 117 177 166 156 46 182 129 57 0 133 63
TOTAL 291 275 2271253 378 493 428 417 658 179 359 133 315 658 339
Table 31: Monthly FG Inventory distribution for Scenario III
We can see from Table 32 that the maximum pallet spaces required for storing the FG
inventory in the year 2008 based on Scenario III are 658 and the average pallet space
inventory over the year is 339.
Figure 20 shows the monthly pallet space inventory distribution for Scenario III.
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Inventory Trend for Scenario III
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Figure 20: Monthly inventory distribution for 2008 for Scenario III
We can see that the Scenario III causes a stock out of Product A in the month of October
for 1 batch due to the shut down in September. This stock out is because of the
assumptions in the model that the first 22 weeks are available for production during the
last six months of 2008. So the model produces at a rate to produce extra every month for
the first five months to meet the demand during the last four weeks of downtime. When I
shifted the downtime in September to represent the actual scenario at TCG, the extra
production prior to September is not sufficient to meet the demand during the downtime.
Section 4.3 compares the result obtained in Scenario III with the current planned MPS at
TCG. We also observe that the end-of-month inventory is quite low particularly in the
month of March and November for Product B even after adding the safety stocks. This
may result in stock out of Product B in these months if there is an increase in demand
during those months.
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4.2.1 Model Improvements
Scenario IV
Similar to Scenario II, I generated Scenario IV to overcome the limitations of Scenario III.
We observed that in Scenario III, we get a stock out of the products. This is because the
demand rates for the two halves of scenario III are based on the actual demand means for
the two halves. Now since the demand for Product B is low in the first six months, the
production is also low. When the demand increases for the next six months, the
production is increased, but the downtime in September results in stock out. To overcome
the stock out I recommend producing at a rate which is based on the total annual demand
and not on the mean demand for the first and the last six months. The total demand for
Product B for the year 2008 is 304 batches. To level the production over the entire year, I
will use the demand rate for Product B during the first six months as 152/23 = 6.6
batches/week and for the last six months as 152/22 = 6.9 batches/week. Table 33 shows
the data used for the model for the first six months.
Unit ProductionSetup Times, Production Rate im P Demand Rate, di
S, (weeks) (batches/week) Time, h (batches/week)(week/batch)
Product A 0.429 22 0.04545 10.34
Product B 0.429 19 0.0526 6.6
Table 32: Model inputs for first six months for Scenario IV
Table 34 shows the excel spreadsheet model calculations for the above. The cycle length
to satisfy the demand for the first six months is 4.889 weeks.
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ti 0.0455 eeks
dl 10.4 batches/week
Model t2 0.0526 eeks
Inputs d2 6.6 batches/week
sI 0.4286 weeks
s2 0.4286 weeks
T 4.889 weeks
Model Q1 51.33 batches
Outputs Q2 32.26 batches
P1 2.33 weeks
1 P2 1.70 Weeks
Table 33: Cycle length Calculation for first six months for Scenario IV
Table 35 shows the model parameters for the first six months of production.
Unit ProductionSetup Times, Production Rate im P Demand Rate, di
S, (weeks) (batches/week) Time, r (batches/week)(week/batch)
Product A 0.429 22 0.04545 10.82
Product B 0.429 22 0.04545 6.8
Table 34: Model inputs for last six months for Scenario IV
Table 36 shows the calculations for the cycle length for the last six months of production.
The cycle length is 4.490 weeks.
ti 0.0455 weeks
dl 10.9 batches/week
Model t2 0.0455 weeks
Inputs d2 6.8 batches/week
sI 0.4286 weeks
s2 0.4286 weeks
Model T 4.490 eeks
Outputs Q1 49.39 atches
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[ Q2P1P2 30.53 batches2.245 weeks1.388 weeks I
Table 35: Cycle length Calculation for last six months for Scenario IV
Table 37 shows the MPS generated based on the Scenario IV.
January - February March April
W~eek 7 1421128 4 11 18 25 3 017 2317 14 21 28
Product A in 950 kg unit 22 22 7.3 2.5 22 22 4.86 4.9 22 2 7.3
Product B Wkly Total 4.5119 8.7 6.66 19 6.6 25.7 9 19 4.5
May June July Au ust
Week 5 12 19 26 2 9 16L23130 7 14 21 28 4 111825
Product A in 950 kg units 22 22 13 22 Downtime 22 22 5.4 11 22 16
Product B Wkly Total 11 17 7.2 22 1.3 19
September October November December
Week 1 29 6 1320 27 3 10 17 24 1 8152229
Product A in 950 kg unit Downtime 22.0 22 4.5 12.6 22 14.8 1.84122 22Product B Wkly Total 8.1 J2010.7Prdc kyTotal ] .2 21. 222
Table 36: Master production schedule for Scenario IV
Table 38 shows the safety stock calculations for Scenario IV.
z STD L Safety(months) Weeks Months Stock
Product A 2 5.775 4.89 1.14 11
Product B 2 8.27 4.89 1.14 18
Table 37: Safety stock calculation for Scenario IV
The inventory calculations for the MPS generated are shown in Table 39.
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Batches
Inventory on Hand JanFeb Mar Apr May Jun Jul Aug Sep Oct No Dec
Product B 18 19 7.9 33.2 50 62.3 47 58.5 54 17 14.811
Product A
Pallet Spaces MaxAverag
Product B 198 20487 365555685520643591184163124201
Product A 44 8913582 49 5.2 43 81 11947142.8137 53 __ 1
TOTAL 242 293 22244716041750 5641724 709 23012051162 2551750 416
Table 38: Monthly FG Inventory distribution for Scenario IV
Figure 21 shows the monthly pallet space inventory distribution for the year 2008 for
Scenario IV.
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Figure 21: Monthly inventory distribution for 2008 for Scenario IV
Hence it shows that the maximum pallet spaces required to store the FG inventory in the
year 2008 based on the Scenario IV are 750. And there are no stock outs in this case. The
average pallet space inventory over the year is 416.
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11 22 34 20.5 12 16.3 11 20.3 30 12 10.7 941
4.3 Evaluation of the Model
To evaluate the different scenarios that I have generated using the campaigning model so
far, I will first show the MPS generated by the planners for the year 2008 and its impact
on the inventory. According to this MPS, the campaign lengths are not fixed. Product A
campaign length varies between 2 to 4 weeks and Product B campaign length varies
between 2 to 2.5 weeks. Table 40 shows the MPS converted into monthly numbers.
Total Monthly Production for Product A and Product B according to TCG MPS
2008
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
Product B 11.00 38.00 25.00 16.00 41.00 0.00 43.00 27.00 0.00 24.00 29.00 50.00 304.00
Product A59.78 33.89 59.33 60.11 24.56 34.00 19.44 37.44 6.22 47.44 49.22 43.67 475.11
Table 39: Master production schedule currently planned by TCG for 2008
Table 41 shows the inventory calculations based on the MPS shown above and the end-
of-month distribution of the pallet space inventory for the year 2008 is shown in Figure
22.
Batches
Inventory on Hand Jan Feb MarAp~ MayJun Jul Augsep Oct NovrDec
Product B_22 10 22 21 22, 47 32 57 59 22 14 9 22
Product A 92 111011021119113711201112189.1 85 149 154.2161 163
Pallet Spaces Max vera e
Product B 242 110 242 231 242 517 352 627 649 242 154 99 242
Product A 368 439 407 476 548 479 447 356 338 195 217 246 252
TOTAL 610 549 649 707 790 996 799 983 987 437 371 345 4941 671
Table 40: Monthly FG Inventory distribution for MPS 2008
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Inventory Trend for TCG Planned MPS
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Figure 22: Monthly pallet space distribution for 2008 for the planned TCG MPS
The figures for inventory on hand are calculated from the available inventory on hand
data for the end of month of May 2007, the production for the rest of the year 2007 and
the demand for the rest of the year 2007. The maximum pallet spaces needed for the year
2008 based on the current MPS planned by TCG is 996. We also observe that the starting
inventory on hand figures are two high in this case as compared to the four scenarios
generated before. So I also tried to find out the optimum starting inventory on hand for
this case as shown in Table 41.
MPS 08
Batches
Inventory On Hand anFeb Ma jrMa un Jul ju e Oct No Dec
Product B 13 1 13 12 13 38 23 48 5013 5 0 13
Product A 44 62 54 71 89 72 64 1.1370.8 .22 13 15
Pallet Spaces MaxAverage
Product B 143 11 143132143 418 253 5281550 143 55 0 143
Product A 176 247 215 284 356 287 255 164 146 3.1 4. 54 60
TOTAL 319 258 358 416 99 705 508 692 696 14679.9 54 203 380
Table 41: Adjusted monthly FG Inventory distribution for MPS 2008
71
We see that the minimum starting on hand inventories in this case to avoid stock out of
the two products are 13 batches for Product B and 44 batches for Product A. But we can
see that keeping the starting inventories at this level only avoids the stock outs which will
result otherwise because of production irregularities. But these do not deal with any
demand variation. For example, if we look at the months January, October and November
for Product B, we can see that the end-of-month inventories are really low and if there is
a change in demand during those months because of the variability then we will have
stock outs of the Product B. So we need to add additional safety stock to take care of the
demand variation. This situation is similar to Scenario I and Scenario III where we
observed that we had stock outs even after adding the safety stocks because the
production was not leveled during the whole year. Therefore, we can conclude that
Scenario 1I and Scenario IV are the best way to plan to production at the Pharmaceutical
Facility 1.
Table 42 shows the comparison between the TCG planned MPS and the different
Scenarios generated based on the campaigning model.
TCG MPS 2008 Campaigning Model Results
Scenario 3 Scenario 4
Average Maximum Average Maximum Average Maximum
Pallet Spaces 671 996 339 658 416 750
Back Orders Product A (Batches) 0 1 0
Back Orders Product B (Batches) 0 0 0
Percentage Savings in Average
Inventory - 49.48 38.00
Percentage Reduction in Maximum
Pallet Space Requirement -_33.94 24.70
Table 42: Inventory comparison between the planned MPS and proposed scenarios
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Hence we can see that if the campaigning model is used to plan the MPS for the year
2008, the inventories can be reduced over the whole year. For further verification of the
actual results, the scenarios I and II can be compared with the new MPS which will be
built for the year 2008 and the decisions can be made on what kind of scenario should be
used.
4.3.1 Model Assumptions
The following assumptions have been made in the model for generating the above
scenarios:
" The production rates are constant. The production variability is not directly taken into
account. But the capacity of the HSM is assumed to be 90% of the total capacity.
During the first half year of 2008 the capacity of HSM is assumed to be 22 batches of
Product A per week and 19 batches of Product B per week. These numbers represent
90% of the total installed capacity for both the products. Same is the case for the
second half of the year.
* The demand for each month is satisfied in the same month. So there are no shipment
delays or any other shipment issues which result in the shipment of demand of a
particular month in the next consecutive month.
" The Pharmaceutical Facility I is never starved. That means the raw materials for
Product A and Product B are available when there production is scheduled.
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4.3.2 Model Limitations
This model is a deterministic model and hence there are inherent limitations in the model.
I have listed some of the limitations which are important to be considered when TCG
tries to implement this model for scheduling their production.
* The model tries to find out the maximum number of changeovers that TCG can make
between the production of Product A and Product B to satisfy the total demand of
both the products and minimize the corresponding inventory levels. Since there are no
cost parameters in this model, the actual cost benefit analysis is not carried out and it
is possible that a scenario which shows the minimum inventory level actually
increases the cost incurred by the company because of more setups.
* This model is based on the assumption that the demand for Product B is 304 batches
for the year 2008. But since I did not have any forecast accuracy data on Product B,
and this is a new product in the market, it is quite likely that the demand will change.
In such an event TCG plans to adjust the number of batches of Product A accordingly.
In such an event, the model calculations will not stay true anymore because the pallet
space requirements for a batch of Product A is different from that for a batch of
Product B.
* This model does not account for the fact that the quality tests can fail sometimes or
are pending, which might result in stock outs.
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5. Conclusions and Recommendations
The goal of this thesis is to minimize the pallet space requirements for stocking the
finished goods in the warehouse. During the process of data collection and system
analysis, I learnt a great deal and also realized some potential issues that exist in the
current system; addressing some of these issues can help in a better control over the
production scheduling and the inventory management. The following list summarizes the
general conclusions that are presented in this thesis:
" The pallet spaces required to stock the finished goods can be reduced compared to the
current plan and the thesis provides management with a model to plan the production
schedule.
" There are many different production schedules which can be developed that meet the
demand. It is up to the management to decide based on the final objective of TCG as
to what scenario will suit the company in the best way.
* The MRP 11 system that TCG currently uses has some limitations. For instance, it is
impossible to track the inventory performance unless a lot of data is collected and
refined which is a very tedious job. A day to day performance metric is required so
that it is easier for the management and the people concerned to stay in a close loop.
This will help the management to continuously monitor the performance of their
inventory model and also to implement the continuous improvement projects.
* This model is based on an analysis that I made during my internship. But presenting
and implementing a model based on such an analysis is not sufficient alone. People
who are actually working for planning and manufacturing need to understand the
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importance of reducing the inventory. It is important to collect more inputs from the
different people involved which will make the implementation of such a solution
much easier.
5.1 Further Research Suggestions
Based on the analysis and the results, I recommend further research into the following
areas:
" The model that I used reduces the inventory but it does not find the optimal minimum
amount of inventory needed to provide the same service level to the customers. Other
research could help find the optimal levels and better production algorithms.
* There is no cost analysis made in this thesis because of the limited time and absence
of the required data. A cost benefit analysis can be carried out to find out the impact
of the model on the cost performance of the plant.
" A research can be conducted to model the production scheduling as an "Economic
Lot Sizing Problem" which will help to find the optimal production lots based on the
comparative inventory holding cost and the setup costs.
" A further research can be carried out on a bigger portion of the TCG supply chain
which can help TCG to optimize the total supply chain costs rather than just the
inventory space in the warehouse.
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